News and information on generic drugs sold in retail pharmacies, as well as their suppliers.
Mycophenolic acid delayed-release tablets had a market value of roughly $156 million, according to IQVIA data from February.
As it moves into its second century in business, Upsher-Smith Labs is focusing on innovating and growing its product offerings while maintaining its high standards.
Sandoz will continue to operate its oral solids and dermatology business as part of the Sandoz U.S. business.
Adderall XR, including generic versions, have a market value of approximately $1.3 billion for the 12 months ending January 2020, according to IQVIA.
Amneal is donating one million hydroxychloroquine sulfate tablets to Texas, following a donation of two million tablets to New York.
Ninety percent of local pharmacists are reporting a shortage of hydroxychloroquine, according to an NCPA survey.
Several pharmaceutical companies are making a commitment to respond to COVID-19 by donating or accelerating the production of hydroxychloroquine.
Zydus Cadila's generic Lamictal will be available in six dosage strengths.
Mylan will enable generic applicants to be eligible for FDA approval if Kaletra is found effective in treating COVID-19.
Zydus Cadila's generic Rytary is indicated to treat Parkinson's disease.
Naloxone hydrochloride injection had a market value of roughly $31 million for the most recent 12 months ended January 2020, according to IQVIA.
Nexium and its generic versions had a market of approximately $70 million for the 12 months ended November 2019, according to IQVIA.
Camber's generic Lyrica is available in dosage strengths of 25, 50, 75, 100, 150, 200, 225, and 300 mg.
The FDA has enacted a shortened regulatory pathway for certain biologics, which will allow for faster approvals and increased competition.